AllergyREBELL Revealing the neuroimmune communication for better treatment outcomes in food allergy
- Coordinator
- Karolinska Institutet, Sweden
- Runs
- 1 November 2026 to 31 October 2028
- Status
- Running
- EU funding
- €252k
- Total cost
- —
- Partners
- 2 organisations in 2 countries
- Type
- Marie Skłodowska-Curie Action
- Grant agreement
- 101277979
What the project is doing
In the project's own words, from its summary on CORDIS.
Current management of potentially life-threatening food allergy (FA) relies on strict food avoidance and emergency medications such as ephedrine auto-injectors for acute reactions. Although oral allergen immunotherapy (OIT), gradual updosing of the offending food, has shown great promise in inducing oral tolerance, these effects are often transient and patients with severe initial symptoms are frequently non-responders.
Thus, there is a pressing need for improved OIT protocols. Neuro-immune dialogue shapes the immune response in allergic asthma: activation of lung-innervating sensory neurons (nociceptors) by allergen exposure amplifies allergic lung inflammation. Comparably, gut-innervating nociceptors can also be activated through allergen exposure, pointing toward a similar neuro-immune dialogue in FA. It is currently unclear how nociceptors communicate with immune cells in FA and how this communication influences OIT outcome.
In AllergyREBELL, I will identify crucial neuroimmune circuits for FA maintenance and tolerance induction by (1) constructing neuroimmune communication maps in the small intestine using a murine FA mouse model in combination with spatial transcriptomics, spatial lipidomics coupled to proteomics and intravital microscopy to track immune cell movements, (2) determining the modulatory capacity of neural factors using a sophisticated immune cell co-culture model and (3) characterising activation profiles of allergy-relevant nociceptors upon allergen exposure.
This project will provide a multi-omics atlas on neuroimmune communication in FA as well as first insights how this communication modulates immune responses critical for tolerance induction. My paramount goal with AllergyREBELL is to identify crucial neuroimmune axes, which can be potentially exploited as therapeutic add-ons to improve OIT for non-responding patients and thus, increasing patients’ quality of life by reducing their constant fear of accidental exposures.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Karolinska Institutet | Stockholm | Sweden | Coordinator |
| Royal Institution for the Advancement of Learning Mcgill University | Montreal | Canada | Associatedpartner |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI